Table 1 The Harwell Ageing screen phenotyping pipeline.

From: Novel gene function revealed by mouse mutagenesis screens for models of age-related disease

Test

Phenotypic Area

Group

Age (weeks)

ECG

Cardiac

All

12

SHIRPA

Neurological

Females (males)

13, 66

Grip strength

Musculoskeletal/neurological

All

13, 66

Slit lamp/opthalmoscope

Vision

All

15, 49, 65, (73)

Optokinetic drum

Vision/neurological

All

15, 49, 65, (73)

Click box

Hearing

Non ahl*

14, 26, 39, 50

Auditory brainstem response+click stimulus

Hearing

Non ahl*

14, 39

Echo-MRI

Growth/body composition

Males (females)

16, 27, 51, 71

DEXA

Musculoskeletal/body composition

Females (males)

16, 51,

X-ray

Musculoskeletal

Females (males)

16, 51, 74

Pupillometry

Vision/neurobehaviour

All

18, 68

Sleep tracking

Neurobehaviour

Females (males)

18, 68

Clinical chemistry

Pathology

Females (males)

28, 53, 80

Fasted bleed

Diabetes/metabolism

Males (females)

17, 28, 52, 80

Fasted insulin

Diabetes/metabolism

Males (females)

33, 57, 72

IPGTT

Diabetes/metabolism

Males (females)

33, 57, 72

  1. ECG, electrocardiogram; DEXA, dual energy X-ray analysis; IPGTT, intraperitoneal glucose tolerance test; MRI, magnetic resonance imaging; SHIRPA, SmithKline Beecham, Harwell, Imperial College and Royal London Hospital phenotype assessment.
  2. A summary and timetable of the core phenotyping tests in the Harwell Ageing Screen, indicating screening time points. In addition to the documented phenotype tests mice are weighed every 3 months up until the age of 12 months and then monthly from 12 months onwards. For the tests where a single sex was initially tested the other sex was screened when outliers were suspected. The screening timetable is flexible and additional screens can be added to confirm outliers depending on the phenotype detected.
  3. *G3 mice mothered by G2 females that do not carry the Cdh23ahl allele.
Back to article page